Australia Backtracks On Cloning Patent For S. Korea Scientist
This article was originally published in PharmAsia News
Executive Summary
Australian authorities are taking a new look at the recent decision to grant a stem cell patent to a disgraced South Korean scientist. Hwang Woo-suk, who lost his job and faced court action after it was revealed he falsified parts of his breakthrough cloning research, was granted an Australia patent for that human embryo cloning technology. IP Australia, the country's intellectual property arm, said the government has delayed the effective date for the patent to become official. The agency would not comment on the delay other than to say it was "investigating the matter." (Click here for more
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.